In terms of effector cells, four paired biopsies from C201 (Figure 1E) and the two paired biopsies from C101 (Figure 1F) showed that murlentamab treatment induced an increase in the proportion or number of both CD16+ cells (in the two patients tested from the C101 study and four out of five patients from C201) and CD16+ cells expressing Granzyme B (in the two patients from the C101 study and in three out of four patients from C201), suggesting a murlentamab-induced activation of macrophages and/or Natural Killer (NK) cells into the tumor microenvironment. This evidence concerns the gene GZMB and neoplasm.